- Q1 2024 Pharming Group NV Earnings Call TranscriptMay 08, 2024€1.05Earnings
- Q4 2023 Pharming Group NV Earnings Call TranscriptMar 14, 2024€1.05Earnings
- Q3 2023 Pharming Group NV Earnings Call TranscriptOct 26, 2023€1.14Earnings
- Q2 2023 Pharming Group NV Earnings Call TranscriptAug 03, 2023€1.08Earnings
- Pharming Group NV Annual Shareholders Meeting TranscriptMay 17, 2023
- Q1 2023 Pharming Group NV Earnings Call TranscriptMay 11, 2023€1.13Earnings
- Pharming Group NV Corporate Analyst Meeting TranscriptMar 27, 2023
- Q4 2022 Pharming Group NV Earnings Call TranscriptMar 16, 2023€1.07Earnings
- Q3 2022 Pharming Group NV Earnings Call TranscriptOct 27, 2022€1.26Earnings
- Q2 2022 Pharming Group NV Earnings Call TranscriptAug 04, 2022€0.761Earnings
- Q1 2022 Pharming Group NV Earnings Call TranscriptMay 12, 2022€0.8535Earnings
- Q4 2021 Pharming Group NV Earnings Call TranscriptMar 24, 2022€0.891Earnings
- Q4 2021 Pharming Group NV Earnings Call TranscriptMar 17, 2022€0.891Earnings
- Pharming Group NV Announces Leniolisib Results Call TranscriptFeb 03, 2022
- Q3 2021 Pharming Group NV Earnings Call TranscriptOct 28, 2021€0.7854Earnings
- Q2 2021 Pharming Group NV Earnings Call TranscriptAug 05, 2021€1Earnings
- Pharming Group NV and Orchard Therapeutics PLC Announce Collaboration to Develop and Commercialize Ex Vivo Autologous HSC Gene Therapy for Hereditary Angioedema Call TranscriptJul 01, 2021
- Pharming Group NV Annual Shareholders Meeting TranscriptMay 19, 2021
- Q1 2021 Pharming Group NV Earnings Call TranscriptMay 13, 2021€1.08Earnings
- Q4 2020 Pharming Group NV Earnings Call TranscriptMar 04, 2021€1.12Earnings
Q3 2023 Pharming Group NV Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the Pharming Group N.V. Third Quarter 2020 Results Conference Call and Webcast. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Sijmen de Vries, CEO of Pharming Group. Please go ahead, sir.
Thank you very much, and good morning or good afternoon, ladies and gentlemen. I'm here with my 3 colleagues, Stephen Toor, our Chief Commercial Officer; Anurag Relan, our Chief Medical Officer; and Jeroen Wakkerman, our Chief Financial Officer, and we are delighted to take you through the third quarter results of this year.
Before I do that, however, I would like to point you to the forward-looking statement slide because we may contain -- this presentation may contain or will probably contain forward-looking statements that, as you know, are statements of future expectations that are based on our current expectations
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)